NAYA - NAYA Biosciences Inc. Projected Sales Volume

NAYA Biosciences Inc - graphic logo of issuer NAYA

The target sales volume of NAYA Biosciences (NAYA) demonstrates scaling potential driven by unique antibodies with high intellectual value, while the value of 0.01 aligns with the current metric. Development currently relies on external funding for early-stage testing due to the absence of a stable cash flow. The primary shield against acquisition by pharma behemoths remains the FLEX-NK platform patents, which are undergoing FDA review amidst a fierce scientific race.

NAYA Biosciences Corp - NAYA Company Expected Sales Volume (period 07/04/2022 - 04/28/2025)

Financial and market metric breakdowns for NAYA Bio (NAYA)

- stock value and consensus price forecast:
- market capitalization statistics:
General company analysis:NAYA Biosciences Inc
Product sample of NAYA Biosciences Inc

This indicator aggregates total market forecasts for the issuer's future cash flows. By analyzing the company's future sales volume, investors assess the expected commercialization of NAYA Biosciences (NAYA) innovative antibodies for cancer treatment. This trend captures a shift in market expectations regarding the scalability of targeted therapy. Comparing current values with the historical trend allows for the timely detection of fundamental shifts, confirming the company's status as a promising scientific innovator.

Main competitors

Projected Sales Volume ONC|HALO (Halozyme) - Company Future Revenue|Projected Sales Volume RVMD (revmed.com)|Company Future Sales Ascentage (AAPG)|CGON: Company Future Sales Volume|Company Expected Sales Volume UroGen Pharma Ltd.|BCAX: Projected Sales Volume|PSNL - Company Future Sales|ERAS (Erasca Oncology) - Projected Sales Volume|Projected Sales Volume Delcath Systems, Inc.|Company Projected Revenue ymabs.com (YMAB)|Company Projected Revenue AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Company Future Sales Volume|Accuray Inc. (ARAY) - Company Expected Sales Volume|SELLAS Life Sciences Group, Inc. - Projected Sales Volume|Company Future Revenue ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Company Projected Revenue|HURA - Company Future Sales|TARA (Protara Therapeutics, Inc.) - Projected Sales Volume|Projected Sales Volume Fate Therapeutics Inc|Projected Sales Volume WHWK|Projected Sales Volume TScan Therapeutics Inc (TCRX)|Company Projected Revenue championsoncology.com CSBR|XBIT - Company Future Sales Volume|CVM - Company Projected Revenue|Company Future Revenue OSTX (OS Therapies)|RADX: Projected Sales Volume|Artiva Biotherapeutics Inc. - Company Future Revenue|ANL (Adlai Nortye) - Projected Sales Volume|Projected Sales Volume verupharma.com|Company Future Sales Volume TPST (tempesttx.com)|Company Future Sales Volume Xilio Therapeutics Inc XLO|Projected Sales Volume RENB (Enochian BioSciences)|Mural Bio - Company Projected Revenue|KAPA - Company Projected Revenue|OnKure Therapeutics (OKUR) - Company Future Sales Volume|GDTC: Projected Sales Volume|Company Expected Sales Volume Curis Corp (CRIS)|APLM (apollomicsinc.com) - Projected Sales Volume|Company Future Sales Volume Tharimmune Corp (THAR)|Projected Sales Volume ADVB|GNPX - Company Expected Sales Volume|Company Projected Revenue calidibio.com CLDI|SBFM - Company Future Sales Volume|XBIO - Company Projected Revenue|SLRX: Company Projected Revenue|Purple Biotech (PPBT) - Company Projected Revenue|AON - Company Future Revenue|Company Future Sales Volume BGNE|Projected Sales Volume Checkpoint Therapeutics Inc.|Projected Sales Volume ELEV|Company Future Sales Volume iCAD ICAD|Projected Sales Volume IKNA (Ikena Oncology, Inc.)|Company Future Revenue NTBL|Viracta Therapeutics, Inc. - Projected Sales Volume|Company Future Revenue MOR (MorphoSys Inc)|AAPGV: Projected Sales Volume